Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

Expected Outcome: This action supports the follow-up to the July 2023 Communication on EU Missions assessment[1]. Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Public procurers, possibly in cooperation with private ones, in the area of cancer-centred healthcare stimulate the competitive development of market-ready, affordable, innovative solutions. The chosen solutions take into consideration the needs of cancer patients living with and beyond cancer through research that supports end-user engagement using participative research models. Procurers create opportunities for European health, technology and medical devices, industrial actors (including start-ups, spin-offs, spin-outs, scale-ups, SMEs) to bring to the market affordable innovations that are cost-efficient, safe and have demonstrated improved health outcomes for cancer patients living with and beyond cancer. Procurers facilitate the commercialisation of innovative solutions for and with cancer patients by their successful suppliers through providing them with first customer references for the validation and first pilot deployment. Policymakers, healthcare providers and professionals, cancer patients and their carers – each in their respective areas – exchange and adopt good practices and the best treatment, technology and medical device solutions that the market can deliver through participative research. Scop…bron

De eisen uit de regeling. Uw situatie bepaalt of u voldoet; dit is geen beschikking.

• Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicinesEU-portaal (SEDIA) · ec.europa.eu7 jul 2026
  Toon brontekst

  Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
  
  Topic: HORIZON-MISS-2027-02-CANCER-05
  Call: HORIZON-MISS-2027-02 — Supporting the implementation of the Cancer Mission
  Programma: Horizon Europe (2021 - 2027)
  
  == Beschrijving ==
  Expected Outcome:
  This action supports the follow-up to the July 2023 Communication on EU Missions assessment[1]. Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
  Public procurers, possibly in cooperation with private ones, in the area of cancer-centred healthcare stimulate the competitive development of market-ready, affordable, innovative solutions.
  The chosen solutions take into consideration the needs of cancer patients living with and beyond cancer through research that supports end-user engagement using participative research models.
  Procurers create opportunities for European health, technology and medical devices, industrial actors (including start-ups, spin-offs, spin-outs, scale-ups, SMEs) to bring to the market affordable innovations that are cost-efficient, safe and have demonstrated improved health outcomes for cancer patients living with and beyond cancer.
  Procurers facilitate the commercialisation of innovative solutions for and with cancer patients by their successful suppliers through providing them with first customer references for the validation and first pilot deployment.
  Policymakers, healthcare providers and professionals, cancer patients and their carers – each in their respective areas – exchange and adopt good practices and the best treatment, technology and medical device solutions that the market can deliver through participative research.
  Scope:
  Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines[2].
  Proposals should address all of the following:
  The focus should be on affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines that benefit cancer patients. Within this topic, it is possible to foresee the transfer and adaptation of solutions and/or interventions from other sectors to healthcare systems. It is open both to proposals requiring improvements based on one specific solution or technology, or medical device as well as to proposals requiring end-to-end solutions that need combinations of different types of innovation.
  The requested innovative solutions for healthcare systems in the areas of affordable cancer technologies, cancer medical devices, or cancer medicines should be clinically validated, piloted or upscaled by the participating procurers in at least five different countries across the EU Member States and Associated Countries.
  Continuous dialogue between the demand and supply side is required for the success of pre-commercial procurement. Therefore the effective involvement of end-users (e.g. academia, clinical teams, cancer patients and their caregivers/families, cancer patient representatives, local or regional medical services, hospitals, production facilities) must be considered in the proposal. To stimulate dialogue with the supply side, procurers are required to organise an open-market consultation before launching the procurement and to promote the call for tenders widely across Europe to potentially interested suppliers.
  Procurers should declare in the proposal their interest to purchase at least one solution resulting from the PCP in case the PCP delivers successful solutions and indicate whether they will (1) procure the solution(s) as part of the PCP or (2) in a separate follow-up procurement after the PCP. In the first case, procurers can implement the project as a fast-track PCP (see general annex H) and foresee the budget to purchase at least one solution during the PCP. In the second case, the procurers must include in the proposal a deliverable that prepares the follow-up procurement to purchase successful solution(s) after the PCP.
  Activities covered should support national healthcare systems and mobilise technical assistance and/or capacity building to other procurers beyond the project to mainstream PCP implementation and to remove obstacles for introducing the innovative solutions for the benefit of cancer patients to be procured into the market.
  [1] EUR-Lex - 52023DC0457 - EN - EUR-Lex
  [2] Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines. This topic does not provide direct funding to developers, industry or research organisations to perform R&D. They will be able to respond to the call for tenders launched by consortia of procurers funded under this call
  
  == Voorwaarden (topic conditions) ==
  ">
  General conditions
  1. Admissibility conditions: Proposal page limit and layout
  described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
  Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
  2. Eligible countries
  described in Annex B of the Work Programme General Annexes.
  A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
  3. Other Eligibility Conditions
  described in Annex B of the Work Programme General Annexes.
  4. Financial and operational capacity and exclusion
  described in Annex C of the Work Programme General Annexes.
  5a. Evaluation and award: Award criteria, scoring and thresholds
  described in Annex D of the Work Programme General Annexes.
  5b. Evaluation and award: Submission and evaluation processes
  The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.
  described in Annex F of the Work Programme General Annexes and the Online Manual.
  5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
  described in Annex F of the Work Programme General Annexes.
  6. Legal and financial set-up of the grants
  The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
  described in Annex G of the Work Programme General Annexes.
  Specific conditions
  described in the specific topic of the Work Programme
  Application and evaluation forms and model grant agreement (MGA):
  Application form templates
  Please use the application form that you will find in the Submission System. You can find examples of standard application forms in the Reference Documents page.
  Evaluation form templates — will be used with the necessary adaptations
  Standard evaluation form (HE PCP PPI)
  Guidance
  HE Programme Guide
  Model Grant Agreements (MGA)
  HE MGA
  Call-specific instructions
  Information on financial support to third parties (HE)
  Additional documents:
  HE Main Work Programme 2026-2027 – 1. General Introduction
  HE Main Work Programme 2026-2027 – 12. Missions
  HE Main Work Programme 2026-2027 – 15. General Annexes
  HE Framework Programme and Rules for Participation Regulation 2021/695
  HE Specific Programme Decision 2021/764
  EU Financial Regulation 2024/2509
  Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
  EU Grants AGA — Annotated Model Grant Agreement
  Funding & Tenders Portal Online Manual
  Funding & Tenders Portal Terms and Conditions
  Funding & Tenders Portal Privacy Statement